Axsome Therapeutics, Inc.

Axsome has had a tremendous start to 2026, including robust year-over-year growth for our commercial business, a recent FDA drug approval, and continued expansion and advancement of our industry-leading development pipeline.   Learn more about our recent milestones and updated guidance here: https://lnkd.in/ePwAnQ4r

The U.S. FDA approved one of our medicines as a treatment for agitation associated with dementia due to Alzheimer's disease, representing a new class of therapies for this debilitating disorder.   Learn more from the FDA about today’s approval here: https://lnkd.in/eVt4dQjP   #AlzheimersDisease #FDAapproval

Today we initiated the CLARITY Phase 3 trial in adults with major depressive disorder with excessive daytime sleepiness symptoms as we continue to advance our innovative CNS pipeline. Learn more here: https://bit.ly/3OqsIw3

Today we reported 4Q and full-year 2025 financial results highlighting the strong growth of our commercial products and advancement across our expanding CNS pipeline. Learn more here: https://bit.ly/4tR6qDO

We’re pleased to announce that the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14 for the management of fibromyalgia, a chronic neurological pain condition in which many patients struggle to find safe and effective symptom relief and treatment options remain limited. Learn more here: https://bit.ly/3NLabKe #fibromyalgia

Our third quarter results highlight our continued commercial performance and execution across our innovative late-stage pipeline. Read more about our progress in today’s news release: https://bit.ly/4nUP2Kl

We’re honored to ring today’s Nasdaq Opening Bell in connection with our Frontiers in Brain Health R&D Day today.   With our growing portfolio of differentiated on-market medicines, and our pipeline of potentially transformative investigational medicines, Axsome is defining the future of clinical practice in brain health to improve the lives of the millions of patients living with serious and difficult-to-treat CNS conditions.   Learn more here: http://bit.ly/4kTPKWC   #Nasdaq #OpeningBell 

We’re reporting earnings for the second quarter of 2025 on August 4, including a call with management to discuss these results and provide a business update. Learn more here: http://bit.ly/461mkSE

Join us at our Frontiers in Brain Health R&D Day for an in-depth look into our innovative CNS pipeline. Hear from physician thought leaders and members of the Axsome management team who will discuss our current indications and clinical development programs in #neurology and #psychiatry. Learn more here: http://bit.ly/45WNH0b

During Alzheimer’s & Brain Awareness Month, we are encouraging people to prioritize brain health and to share resources that could help people affected by Alzheimer’s disease and other CNS disorders.    Learn more about our efforts and shared resources here: https://bit.ly/4k2Nqfv   #AlzheimersAwareness #AlzheimersAwarenessMonth